Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul Maier
AddedMar 31, 2024
UpdatedMay 31, 2026
Paul Maier

Paul Maier

Board Member, International Stem Cell

CrunchbaseLinkedIn

Paul Maier's Career

International Stem Cell
International Stem Cell

Carlsbad, CA, US

Board Member· Board
Eton Pharmaceuticals
Eton Pharmaceuticals

Deer Park, IL, US

Board Member· Board
Biological Dynamics
Biological Dynamics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul Maier's Career

International Stem Cell
International Stem Cell
Public$7.5M292005Carlsbad, CA, US
Board Member· Board

Leadership at International Stem Cell

Bill AdamsBill AdamsFounder
Andrey SemechkinAndrey SemechkinBoard Member
Donald A WrightDonald A WrightBoard Member
Russell KernRussell KernBoard Member

Similar to International Stem Cell

ImStem BiotechnologyImStem BiotechnologyFarmington, NM, USCell Therapyest. 2012ImStem BiotechnologyFarmington, NM, US · est. 2012

Imstem Biotechnology develops cell therapeutic products for tissue repair and disease treatment.

Public · $1.1M20
Stemedica Cell TechnologiesStemedica Cell TechnologiesSan Diego, CA, USCell Therapy, Therapeuticsest. 2005Stemedica Cell TechnologiesSan Diego, CA, US · est. 2005

Stemedica Cell Technologies: Developing and commercializing cell and protein therapies for medical needs.

Series B · $67M175
StemcyteStemcyteBaldwin Park, CA, USStem Cell Productsest. 1997StemcyteBaldwin Park, CA, US · est. 1997

US-based StemCyte Inc. provides umbilical cord blood stem cell products for life-threatening disease treatments.

Public · $2.5M750
Eton Pharmaceuticals
Eton Pharmaceuticals
Public$38.1M282017Deer Park, IL, US
Board Member· Board

Leadership at Eton Pharmaceuticals

Mark L. BaumMark L. BaumFounder
Charles CasamentoCharles CasamentoBoard Member
Sean BrynjelsenSean BrynjelsenCEO
Norbert RiedelNorbert RiedelBoard Member
Biological Dynamics
Biological Dynamics
Series D$43.8M992010San Diego, CA, US
Board Member· Board

Leadership at Biological Dynamics

David CharlotDavid CharlotCo-Founder
Raj KrishnanRaj KrishnanCo-Founder
Sanjay JhaSanjay JhaBoard Member
Irwin JacobsIrwin JacobsBoard Member
Martin J WygodMartin J WygodBoard Member
Kip MillerKip MillerBoard Member

Paul Maier's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · Kakao

People Similar to Paul Maier

Jill HoweJill HoweBoard Member · Biora TherapeuticsJohn SantoleriJohn SantoleriBoard Member · Bioenergy DevCoMatthew RosMatthew RosBoard Member · Cogent BiosciencesSusan KimSusan KimBoard Member · Pivot BioMichael SmithMichael SmithBoard Member · ProterraRobert HuginRobert HuginBoard Member · Celgene